VistaGen Therapeutics, Inc.VTGNNASDAQ
Loading
VTGN Revenue Growth (YoY Quarterly)•+29.49%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+29.49%
-11.5pp
-51.28%
-92.3pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+37.52%
+20.8pp
+37.52%
+20.8pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -43.12% | -107.60% | +190.48% | +40.98% | +29.49% |
| Gross Profit Growth | -43.12% | -107.60% | -10.71% | +40.98% | -51.28% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +108.95% | +13.62% | +4.34% | +16.70% | +37.52% |
| Weighted Average Shares Diluted Growth | +108.95% | +13.62% | +4.34% | +16.70% | +37.52% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -29.57% | -31.79% | -39.30% | -21.04% | -29.52% |
| Book Value per Share Growth | -68.51% | -45.79% | -48.09% | -38.86% | -54.36% |
| Debt Growth | -24.03% | -28.82% | +18.39% | +3.96% | -16.70% |
| R&D Expense Growth | +149.14% | +37.25% | +52.69% | +55.80% | +25.33% |
| SG&A Expenses Growth | +7.74% | +3.71% | -4.31% | +4.79% | +35.61% |
1 / 4